HIO

Navrogen is a biotechnology company focused on the discovery of tumor-produced Humoral Immuno-Oncology (HIO) factors that suppress the patient's immune response and limit the efficacy of antibody-based therapies. The company utilizes its proprietary HIO discovery and Block-Removed Immunoglobulin Technology (BRITE) platforms to identify and engineer HIO-refractory therapeutic agents, including monoclonal antibodies, antibody-drug conjugates (ADCs), and T-cell engagers. Navrogen's pipeline features several first-in-class candidates, such as NAV-001, an anti-mesothelin ADC, and NAV-006, a next-generation rituximab designed to overcome immunosuppression in follicular lymphoma. By targeting these novel immunosuppressive pathways, Navrogen aims to provide alternative treatment options for patients with HIO-positive cancers who are less responsive to current standard-of-care immunotherapies.